Dysport-to-Botox Conversion Ratios in Practice: Pricing and Dosing When You Run Both

AbobotulinumtoxinA (Dysport) and onabotulinumtoxinA (Botox) are different molecules with different unit definitions, which is why a conversion exists at all. The widely used anchor is 2.5:1, with many practices and studies citing up to 3:1 depending on indication, area, and injector preference. Dysport also has its own diffusion characteristics that some injectors prefer for broad areas like the forehead and find less ideal where tight control matters.

Treat 2.5:1 as the house anchor and let your injectors adjust within a defined band by area and patient — but define the band. The danger isn't the ratio itself; it's two injectors silently using different conversions, so the "same" treatment costs different amounts of product depending on who's holding the syringe.

The pricing trap: don't let patients arbitrage you

Here's the mistake that quietly damages two-toxin practices: pricing both products per unit and advertising Dysport's lower per-unit number as if it were a deal. A patient hears "Dysport is only a few dollars a unit" and feels great — until checkout, when they're billed for 50 or 60 units against the 20 they'd expect from Botox. Even when the total is perfectly fair, the experience feels like a bait-and-switch, and a savvy patient will run the conversion math you didn't surface and conclude you overcharged somewhere.

The clean fix is to price by area or by treatment, not by raw unit, at least in how you present it to patients. "Glabella is $X" or "full upper face is $Y" is coherent regardless of which molecule delivers it. Internally you still track units and loaded cost per product; externally the patient sees a price that doesn't invite arbitrage. Per-unit pricing has its place for transparency-minded markets, but if you run both toxins, per-area framing removes the single most common source of patient confusion and perceived unfairness.

Keeping injectors consistent

Two toxins means two reconstitution protocols, two dosing conversions, and two sets of muscle memory. Without standards, you get drift: one injector running Dysport heavy, another light, product cost wandering treatment to treatment. Lock down a single reconstitution standard per product, a documented conversion band, and a per-area dosing reference so that a glabella costs roughly the same amount of product no matter who treats it. Consistency here is both a clinical quality issue and a margin-control issue.

The volume cost nobody mentions

Running both products feels like patient-friendly choice, and it can be. But it splits your purchasing across two manufacturers, which can drop you out of a volume tier or weaken your loyalty standing on your primary toxin — quietly raising the loaded cost of the product you use most. That's the real price of optionality, and it's why the second toxin should earn its place by serving genuine demand, not just sitting on the shelf as a courtesy.

What to do

• Set 2.5:1 as the house conversion anchor, with a defined adjustment band by area, and put it in writing so injectors don't freelance.
• Present pricing per area or per treatment, not per raw unit, so patients can't (and don't try to) arbitrage one toxin against the other.
• Standardize reconstitution and per-area dosing for each product so cost-per-treatment is consistent across injectors.
• Watch your tier and loyalty position. If the second toxin is dragging your primary product's loaded cost up by splitting volume, make sure the demand it serves is worth it.

Two toxins, run with discipline, is a legitimate and patient-friendly offering. Two toxins run on textbook ratios and per-unit pricing is a steady drip of confused patients and wandering margin. The molecule is chemistry; the conversion and the price card are management.